AstraZeneca's Lung Cancer Drug Combination Fails to Meet Primary Endpoint in Trial

Deep News12-22 22:20

AstraZeneca PLC announced that its experimental drug ceralasertib, combined with the approved cancer treatment Imfinzi, did not achieve the primary endpoint in a late-stage clinical trial for advanced lung cancer.

The UK-based pharmaceutical company stated on Monday that the study results showed the ceralasertib combination failed to meet the primary goal of overall survival compared to standard therapy in patients with locally advanced or metastatic non-small cell lung cancer.

AstraZeneca noted that the combination of ceralasertib and Imfinzi was generally well-tolerated, with no new safety concerns identified.

The company added that the trial evaluated the drug combination's efficacy in lung cancer patients who had undergone prior treatment and whose tumors stopped responding to existing therapies. Ceralasertib targets a protein critical for DNA damage response and cell survival, and it can be used alongside other drugs that enhance the body's immune response to treat tumors.

Susan Galbraith, Executive Vice President of Oncology R&D at AstraZeneca, said, "While we are disappointed with this outcome, we remain committed to pioneering new medicines through our industry-leading portfolio to address the urgent need for improved treatment outcomes in lung cancer patients."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1137078943?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-22 22:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137078943","market":"fut","top_or_hot":-1,"title":"AstraZeneca's Lung Cancer Drug Combination Fails to Meet Primary Endpoint in Trial","media":"Deep News","content":"<p>AstraZeneca PLC announced that its experimental drug ceralasertib, combined with the approved cancer treatment Imfinzi, did not achieve the primary endpoint in a late-stage clinical trial for advanced lung cancer.</p>\n<p>The UK-based pharmaceutical company stated on Monday that the study results showed the ceralasertib combination failed to meet the primary goal of overall survival compared to standard therapy in patients with locally advanced or metastatic non-small cell lung cancer.</p>\n<p>AstraZeneca noted that the combination of ceralasertib and Imfinzi was generally well-tolerated, with no new safety concerns identified.</p>\n<p>The company added that the trial evaluated the drug combination's efficacy in lung cancer patients who had undergone prior treatment and whose tumors stopped responding to existing therapies. Ceralasertib targets a protein critical for DNA damage response and cell survival, and it can be used alongside other drugs that enhance the body's immune response to treat tumors.</p>\n<p>Susan Galbraith, Executive Vice President of Oncology R&D at AstraZeneca, said, \"While we are disappointed with this outcome, we remain committed to pioneering new medicines through our industry-leading portfolio to address the urgent need for improved treatment outcomes in lung cancer patients.\"</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca's Lung Cancer Drug Combination Fails to Meet Primary Endpoint in Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca's Lung Cancer Drug Combination Fails to Meet Primary Endpoint in Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-12-22 22:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AstraZeneca PLC announced that its experimental drug ceralasertib, combined with the approved cancer treatment Imfinzi, did not achieve the primary endpoint in a late-stage clinical trial for advanced lung cancer.</p>\n<p>The UK-based pharmaceutical company stated on Monday that the study results showed the ceralasertib combination failed to meet the primary goal of overall survival compared to standard therapy in patients with locally advanced or metastatic non-small cell lung cancer.</p>\n<p>AstraZeneca noted that the combination of ceralasertib and Imfinzi was generally well-tolerated, with no new safety concerns identified.</p>\n<p>The company added that the trial evaluated the drug combination's efficacy in lung cancer patients who had undergone prior treatment and whose tumors stopped responding to existing therapies. Ceralasertib targets a protein critical for DNA damage response and cell survival, and it can be used alongside other drugs that enhance the body's immune response to treat tumors.</p>\n<p>Susan Galbraith, Executive Vice President of Oncology R&D at AstraZeneca, said, \"While we are disappointed with this outcome, we remain committed to pioneering new medicines through our industry-leading portfolio to address the urgent need for improved treatment outcomes in lung cancer patients.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2417539215.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","start_time":0,"source_url":"","article_id":"1137078943","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137078943","pubTimestamp":1766413231,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"AstraZeneca PLC announced that its experimental drug ceralasertib, combined with the approved cancer treatment Imfinzi, did not achieve the primary endpoint in a late-stage clinical trial for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4007":"制药","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","AZN":"阿斯利康","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4568":"美国抗疫概念","BK4588":"碎股","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4585":"ETF&股票定投概念","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC"},"translate_title":"阿斯利康肺癌药物组合在试验中未能达到主要终点","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1},"content_text":"AstraZeneca PLC announced that its experimental drug ceralasertib, combined with the approved cancer treatment Imfinzi, did not achieve the primary endpoint in a late-stage clinical trial for advanced lung cancer.\nThe UK-based pharmaceutical company stated on Monday that the study results showed the ceralasertib combination failed to meet the primary goal of overall survival compared to standard therapy in patients with locally advanced or metastatic non-small cell lung cancer.\nAstraZeneca noted that the combination of ceralasertib and Imfinzi was generally well-tolerated, with no new safety concerns identified.\nThe company added that the trial evaluated the drug combination's efficacy in lung cancer patients who had undergone prior treatment and whose tumors stopped responding to existing therapies. Ceralasertib targets a protein critical for DNA damage response and cell survival, and it can be used alongside other drugs that enhance the body's immune response to treat tumors.\nSusan Galbraith, Executive Vice President of Oncology R&D at AstraZeneca, said, \"While we are disappointed with this outcome, we remain committed to pioneering new medicines through our industry-leading portfolio to address the urgent need for improved treatment outcomes in lung cancer patients.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137078943","isCrawlerRequest":true}